日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis

情绪困扰会降低复发性高级别胶质瘤中免疫检查点阻断疗法的疗效:来自肿瘤原位液分析的启示

Wang, Dayang; Zhang, Jiubing; Liu, Guanzheng; Bu, Chaojie; Wei, Shaobin; Li, Minghao; Lv, Guangming; Sheng, Zhiyuan; Mei, Jie; Yan, Zhaoyue; Gao, Yushuai; Zhao, Ruijiao; Shi, Yujie; Wang, Meiyun; Bu, Xingyao

Clinical characteristics and prognostic analysis of calcified glioblastoma

钙化胶质母细胞瘤的临床特征和预后分析

Li, Mengda; Li, Juntao; Guo, Yongji; Li, Zhixiao; Liu, Guanzheng; Bu, Xingyao; Ma, Chunxiao

New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma

原发性中枢神经系统淋巴瘤靶向治疗和免疫治疗的新希望与挑战

Yang, Chuanwei; Ren, Xiaohui; Cui, Yong; Jiang, Haihui; Li, Ming; Yu, Kefu; Shen, Shaoping; Li, Mingxiao; Zhang, Xiaokang; Zhao, Xuzhe; Zhu, Qinghui; Bu, Xingyao; Lin, Song

Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas

动态肿瘤原位液循环肿瘤DNA术后可有效预测胶质母细胞瘤的复发和临床获益

Zhang, Jiubing; Liu, Guanzheng; Wang, Dayang; Bu, Chaojie; Lv, Guangming; Zhang, Ziyue; Guo, Guangzhong; Gao, Yushuai; Yan, Zhaoyue; Ma, Chunxiao; Liu, Gang; Zhao, Ruijiao; Wang, Meiyun; Bu, Xingyao

Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment

利用肿瘤原位液中的肿瘤DNA追踪一线治疗下胶质瘤的演变

Yu, Jinliang; Gao, Yushuai; Zhang, Jiubing; Wang, Dayang; Deng, Kaiyuan; Wu, Shuang; Zhang, Ziyue; Yan, Zhaoyue; Liu, Guanzheng; Dong, Liujian; Li, Tao; Feng, Shubin; Bu, Xingyao

Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study

动态监测循环肿瘤DNA预测术后胶质瘤非原位复发风险:一项前瞻性队列研究

Guo, Guangzhong; Zhang, Ziyue; Zhang, Jiubing; Wang, Dayang; Xu, Sensen; Wu, Shuang; Deng, Kaiyuan; Bu, Yage; Sheng, Zhiyuan; Yu, Jinliang; Gao, Yushuai; Yan, Zhaoyue; Zhao, Ruijiao; Wang, Meiyun; Li, Tianxiao; Bu, Xingyao

Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis

利用肿瘤原位液循环肿瘤DNA分析预测复发性胶质母细胞瘤对免疫检查点抑制剂和低剂量贝伐单抗的临床疗效

Guo, Guangzhong; Zhang, Ziyue; Zhang, Jiubing; Wang, Dayang; Xu, Sensen; Liu, Guanzheng; Gao, Yushuai; Mei, Jie; Yan, Zhaoyue; Zhao, Ruijiao; Wang, Meiyun; Li, Tianxiao; Bu, Xingyao

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

复发性胶质母细胞瘤中肿瘤原位液循环肿瘤DNA的动态变化可预测免疫检查点阻断联合低剂量贝伐珠单抗的治疗效果

Wang, Dayang; Zhang, Jiubing; Bu, Chaojie; Liu, Guanzheng; Guo, Guangzhong; Zhang, Ziyue; Lv, Guangming; Sheng, Zhiyuan; Yan, Zhaoyue; Gao, Yvshuai; Wang, Meiyun; Liu, Gang; Zhao, Ruijiao; Li, Tianxiao; Ma, Chunxiao; Bu, Xingyao

Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid

通过对肿瘤原位液中游离肿瘤DNA进行连续分析,追踪脑胶质瘤一线治疗期间的肿瘤演变。

Sheng, Zhiyuan; Bu, Chaojie; Mei, Jie; Xu, Sensen; Zhang, Ziyue; Guo, Guangzhong; Gao, Yushuai; Xing, Liyuan; Chen, Zhongcan; Hernesniemi, Juha; Zemmar, Ajmal; Bu, Xingyao

Genomic alterations of oligodendrogliomas at distant recurrence

远处复发时少突胶质细胞瘤的基因组改变

Liu, Guanzheng; Bu, Chaojie; Guo, Guangzhong; Zhang, Zhiyue; Sheng, Zhiyuan; Deng, Kaiyuan; Wu, Shuang; Xu, Sensen; Bu, Yage; Gao, Yushuai; Wang, Meiyun; Liu, Gang; Kong, Lingfei; Li, Tianxiao; Li, Ming; Bu, Xingyao